Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

(2016) Stacey M Stein et al.   BRITISH JOURNAL OF CANCER

Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

(2016) Hideki Ueno et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

(2016) Pascal Hammel et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

(2016) Katsuhiko Uesaka et al.   LANCET

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

(2016) Mustafa Suker et al.   LANCET ONCOLOGY

Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis

(2016) Michael Tachezy et al.   SURGERY

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential

(2016) Erik S. Knudsen et al.   Oncotarget

Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience

(2015) Ulrich Nitsche et al.   ANNALS OF SURGICAL ONCOLOGY

Stromal biology and therapy in pancreatic cancer: a changing paradigm

(2015) Albrecht Neesse et al.   GUT

Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection

(2015) Sophie Schneitler   WORLD JOURNAL OF GASTROENTEROLOGY

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

(2014) Takuji Okusaka et al.   CANCER SCIENCE

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

(2013) Hideki Ueno et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pan

(2013) Sohei Satoi et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Reoperation for Locally Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma Following Primary Pancreatic Resection

(2012) Ryan M. Thomas et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

(2011) Patrick J. Loehrer et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer

(2010) Takuji Okusaka et al.   CANCER SCIENCE

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

(2010) John P. Neoptolemos et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506

(2010) H. Ishii et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

(2009) H Ueno et al.   BRITISH JOURNAL OF CANCER

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study

(2008) B. Chauffert et al.   ANNALS OF ONCOLOGY